U.S. market Closed. Opens in 11 hours 58 minutes

SPRY | ARS Pharmaceuticals, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue30.00K1.32M5.51M17.84MN/A
Cost of Revenue73.00K17.32M20.27M14.07M1.55M
Gross Profit-43.00K-16.00M-14.77M3.77M-1.55M
Operating Expenses67.48M36.83M24.96M18.30M22.52M
Selling, General & Admin47.21M18.46M4.69M4.23M1.02M
Research & Development20.27M18.38M20.27M14.07M21.50M
Other Operating Expenses13.15M974.00K-789.00K-596.00KN/A
Operating Income-67.52M-35.52M-19.45M-469.00K-24.07M
Other Expenses / Income13.15M834.00K-789.00K-596.00K100.00K
Before Tax Income-54.37M-34.68M-20.24M-1.06M-23.97M
Income Tax Expenses-94.89K-694.00K-230.56K-200.30KN/A
Net Income-54.37M-33.99M-20.24M-1.06M-23.97M
Interest ExpensesN/A-834.00K106.00K29.00KN/A
Basic Shares Outstanding95.22M39.96M28.87M34.70M33.07M
Diluted Shares Outstanding95.22M39.96M28.87M34.70M33.07M
EBITDA-67.45M-35.06M-19.45M-463.00K-22.52M
EBITDA Margin-224,823.33%-2,663.91%-353.21%-2.60%0.00%
EBIT-54.46M-35.52M-20.37M-1.24M-23.97M
EBIT Margin-181,532.98%-2,698.78%-369.92%-6.93%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙